85 related articles for article (PubMed ID: 23418928)
1. Immune cell profile of sentinel lymph nodes in patients with malignant melanoma - FOXP3+ cell density in cases with positive sentinel node status is associated with unfavorable clinical outcome.
Mohos A; Sebestyén T; Liszkay G; Plótár V; Horváth S; Gaudi I; Ladányi A
J Transl Med; 2013 Feb; 11():43. PubMed ID: 23418928
[TBL] [Abstract][Full Text] [Related]
2. Molecular analysis of melanoma-induced sentinel lymph node immune dysfunction.
Lee JH; Chen Y; Chan JL; Qian YW; Goydos JS
Cancer Immunol Immunother; 2011 May; 60(5):685-92. PubMed ID: 21327637
[TBL] [Abstract][Full Text] [Related]
3. Density of DC-LAMP(+) mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor.
Ladányi A; Kiss J; Somlai B; Gilde K; Fejos Z; Mohos A; Gaudi I; Tímár J
Cancer Immunol Immunother; 2007 Sep; 56(9):1459-69. PubMed ID: 17279413
[TBL] [Abstract][Full Text] [Related]
4. The numbers of FoxP3+ lymphocytes in sentinel lymph nodes of breast cancer patients correlate with primary tumor size but not nodal status.
Gupta R; Babb JS; Singh B; Chiriboga L; Liebes L; Adams S; Demaria S
Cancer Invest; 2011 Jul; 29(6):419-25. PubMed ID: 21649468
[TBL] [Abstract][Full Text] [Related]
5. Identification of identical TCRs in primary melanoma lesions and tumor free corresponding sentinel lymph nodes.
Straten Pt; Dahl C; Schrama D; Pedersen LØ; Andersen MH; Seremet T; Bröcker EB; Guldberg P; Becker JC
Cancer Immunol Immunother; 2006 May; 55(5):495-502. PubMed ID: 16001163
[TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of B-cell density in cutaneous melanoma.
Ladányi A; Kiss J; Mohos A; Somlai B; Liszkay G; Gilde K; Fejös Z; Gaudi I; Dobos J; Tímár J
Cancer Immunol Immunother; 2011 Dec; 60(12):1729-38. PubMed ID: 21779876
[TBL] [Abstract][Full Text] [Related]
7. Selective accumulation of differentiated FOXP3(+) CD4 (+) T cells in metastatic tumor lesions from melanoma patients compared to peripheral blood.
Jandus C; Bioley G; Speiser DE; Romero P
Cancer Immunol Immunother; 2008 Dec; 57(12):1795-805. PubMed ID: 18414854
[TBL] [Abstract][Full Text] [Related]
8. Langerhans Cells in Sentinel Lymph Nodes from Melanoma Patients.
Gerlini G; Susini P; Sestini S; Brandani P; Giannotti V; Borgognoni L
Cancers (Basel); 2024 May; 16(10):. PubMed ID: 38791968
[TBL] [Abstract][Full Text] [Related]
9. A lactate-SREBP2 signaling axis drives tolerogenic dendritic cell maturation and promotes cancer progression.
Plebanek MP; Xue Y; Nguyen YV; DeVito NC; Wang X; Holtzhausen A; Beasley GM; Theivanthiran B; Hanks BA
Sci Immunol; 2024 May; 9(95):eadi4191. PubMed ID: 38728412
[TBL] [Abstract][Full Text] [Related]
10. Tumor-associated macrophages and tumor-infiltrating lymphocytes in canine cutaneous and subcutaneous mast cell tumors.
Bertola L; Pellizzoni B; Giudice C; Grieco V; Ferrari R; Chiti LE; Stefanello D; Manfredi M; De Zani D; Recordati C
Vet Pathol; 2024 Apr; ():3009858241244851. PubMed ID: 38647163
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the effect of autoclaved and non-autoclaved live soil exposure on the mouse immune system : Effect of soil exposure on immune system.
Kummola L; González-Rodríguez MI; Marnila P; Nurminen N; Salomaa T; Hiihtola L; Mäkelä I; Laitinen OH; Hyöty H; Sinkkonen A; Junttila IS
BMC Immunol; 2023 Sep; 24(1):29. PubMed ID: 37689649
[TBL] [Abstract][Full Text] [Related]
12. Comparison of [
Ooms M; von Mallek D; Kaiser HJ; Hölzle F; Mottaghy FM; Modabber A
Eur J Nucl Med Mol Imaging; 2023 Feb; 50(3):870-880. PubMed ID: 36305908
[TBL] [Abstract][Full Text] [Related]
13. New Therapeutic Approaches for Conjunctival Melanoma-What We Know So Far and Where Therapy Is Potentially Heading: Focus on Lymphatic Vessels and Dendritic Cells.
Peil J; Bock F; Kiefer F; Schmidt R; Heindl LM; Cursiefen C; Schlereth SL
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163401
[TBL] [Abstract][Full Text] [Related]
14. Single-Cell Immune Mapping of Melanoma Sentinel Lymph Nodes Reveals an Actionable Immunotolerant Microenvironment.
Yaddanapudi K; Stamp BF; Subrahmanyam PB; Smolenkov A; Waigel SJ; Gosain R; Egger ME; Martin RCG; Buscaglia R; Maecker HT; McMasters KM; Chesney JA
Clin Cancer Res; 2022 May; 28(10):2069-2081. PubMed ID: 35046061
[TBL] [Abstract][Full Text] [Related]
15. Detection of cancer metastasis: past, present and future.
Alix-Panabieres C; Magliocco A; Cortes-Hernandez LE; Eslami-S Z; Franklin D; Messina JL
Clin Exp Metastasis; 2022 Feb; 39(1):21-28. PubMed ID: 33961169
[TBL] [Abstract][Full Text] [Related]
16. Exosomal miR-208b related with oxaliplatin resistance promotes Treg expansion in colorectal cancer.
Ning T; Li J; He Y; Zhang H; Wang X; Deng T; Liu R; Li H; Bai M; Fan Q; Zhu K; Ying G; Ba Y
Mol Ther; 2021 Sep; 29(9):2723-2736. PubMed ID: 33905821
[TBL] [Abstract][Full Text] [Related]
17. Defective levels of both circulating dendritic cells and T-regulatory cells correlate with risk of recurrence in cutaneous melanoma.
Tucci M; Stucci LS; Mannavola F; Passarelli A; D'Oronzo S; Lospalluti L; Giudice G; Silvestris F
Clin Transl Oncol; 2019 Jul; 21(7):845-854. PubMed ID: 30470990
[TBL] [Abstract][Full Text] [Related]
18. Targeting Chemokines and Chemokine Receptors in Melanoma and Other Cancers.
Jacquelot N; Duong CPM; Belz GT; Zitvogel L
Front Immunol; 2018; 9():2480. PubMed ID: 30420855
[TBL] [Abstract][Full Text] [Related]
19. Lymph Node Cellular Dynamics in Cancer and HIV: What Can We Learn for the Follicular CD4 (Tfh) Cells?
Poultsidi A; Dimopoulos Y; He TF; Chavakis T; Saloustros E; Lee PP; Petrovas C
Front Immunol; 2018; 9():2233. PubMed ID: 30319664
[TBL] [Abstract][Full Text] [Related]
20. Bad company: Microenvironmentally mediated resistance to targeted therapy in melanoma.
Almeida FV; Douglass SM; Fane ME; Weeraratna AT
Pigment Cell Melanoma Res; 2019 Mar; 32(2):237-247. PubMed ID: 30216694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
